CSIMarket
 


Ascendis Pharma A  (ASND)
Other Ticker:  
 

Ascendis Pharma A's Tangible Leverage Ratio

ASND's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to repayements of liabilities of 0% Ascendis Pharma A improved Tangible Leverage Ratio in forth quarter 2022 to 3.14, a new company high.

Within Major Pharmaceutical Preparations industry in the forth quarter 2022, 467 other companies have achieved lower Tangible Leverage Ratio than Ascendis Pharma A in the IV Quarter 2022. While Tangible Leverage Ratio total ranking has deteriorated compared to the third quarter 2022 from 3521 to 3761 .

Explain Tangible Leverage Ratio?
What is ASND Market Share?
What are ASND´s Total Liabilities?


ASND Tangible Leverage Ratio (Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Tangible Equity Change -70.2 % -70.2 % -70.2 % -70.2 % 5.36 %
Y / Y Total Liabilities Change 310.56 % 310.56 % 310.56 % 310.56 % 42.67 %
Tangible Leverage Ratio MRQ 3.14 3.14 3.14 3.14 0.23
ASND's Total Ranking # 3761 # 3521 # 3680 # 3680 # 422
Seq. Tangible Equity Change 0 % 0 % 0 % -70.2 % 0 %
Seq. Total Liabilities Change 0 % 0 % 0 % 310.56 % 0 %



Tangible Leverage Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 468
Healthcare Sector # 939
Overall Market # 3761


Tangible Leverage Ratio Statistics
High Average Low
3.14 0.97 0.13
(Dec 31 2022)   (Dec 31 2019)




Financial Statements
Ascendis Pharma A's Tangible Equity $ 295 Millions Visit ASND's Balance sheet
Ascendis Pharma A's Total Liabilities $ 926 Millions Visit ASND's Balance sheet
Source of ASND's Sales Visit ASND's Sales by Geography


Cumulative Ascendis Pharma A's Tangible Leverage Ratio

ASND's Tangible Leverage Ratio for the trailling 12 Months

ASND Tangible Leverage Ratio

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Tangible Equity TTM Growth -70.2 % -70.2 % -70.2 % -70.2 % 5.36 %
Y / Y Total Liabilities TTM Growth 310.56 % 310.56 % 310.56 % 310.56 % 42.67 %
Tangible Leverage Ratio TTM 3.14 1.6 0.9 0.49 0.23
Total Ranking TTM # 3717 # 5 # 8 # 4 # 672
Seq. Tangible Equity TTM Growth 0 % 0 % 0 % -70.2 % 0 %
Seq. Total Liabilities TTM Growth 0 % 0 % 0 % 310.56 % 0 %


On the trailing twelve months basis Despite of the repayements of liabilities of 0% in the trailing twelve months ending in IV Quarter 2022, Tangible Leverage Ratio improved to 3.14, a new company high.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 466, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Ascendis Pharma A. While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2022, compared to the prior period, from 5 to 3717.

Explain Tangible Leverage Ratio?
What is ASND Market Share?
What are ASND´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 467
Healthcare Sector # 944
Within the Market # 3717


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
3.14 0.42 0.13
(Dec 31 2022)   (Dec 31 2019)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioDec 31 2022 MRQ Total LiabilitiesDec 31 2022 MRQ Tangible Equity
Applied Therapeutics inc   8.45 $ 34.302  Millions$ 4.061  Millions
Abbott Laboratories  8.28 $ 30,230.000  Millions$ 3,652.000  Millions
Ultragenyx Pharmaceutical Inc   7.97 $ 1,179.692  Millions$ 147.983  Millions
Sarepta Therapeutics Inc   7.03 $ 2,654.172  Millions$ 377.372  Millions
Assertio Holdings inc   6.79 $ 188.188  Millions$ 27.729  Millions
Effector Therapeutics Inc   6.46 $ 25.181  Millions$ 3.896  Millions
Aslan Pharmaceuticals Limited  6.31 $ 52.820  Millions$ 8.365  Millions
Innovation Pharmaceuticals Inc   6.06 $ 5.610  Millions$ 0.925  Millions
Horizon Therapeutics Public Limited Company  5.96 $ 3,495.974  Millions$ 586.859  Millions
Societal Cdmo Inc   5.80 $ 91.921  Millions$ 15.854  Millions
Axsome Therapeutics Inc   5.61 $ 221.920  Millions$ 39.586  Millions
Orgenesis Inc   5.53 $ 61.857  Millions$ 11.190  Millions
Sellas Life Sciences Group Inc   5.48 $ 16.092  Millions$ 2.937  Millions
China Pharma Holdings Inc   5.44 $ 13.494  Millions$ 2.483  Millions
Qualigen Therapeutics Inc   5.16 $ 11.848  Millions$ 2.295  Millions
Adc Therapeutics Sa  4.96 $ 440.441  Millions$ 88.727  Millions
Intercept Pharmaceuticals inc   4.95 $ 460.634  Millions$ 93.077  Millions
Aravive Inc   4.83 $ 51.496  Millions$ 10.657  Millions
Summit Therapeutics Inc   4.31 $ 537.514  Millions$ 124.856  Millions
Maravai Lifesciences Holdings Inc   4.28 $ 1,734.009  Millions$ 404.912  Millions
Opko Health Inc   4.26 $ 605.611  Millions$ 142.277  Millions
Omeros Corp  4.17 $ 357.289  Millions$ 85.684  Millions
Emergent Biosolutions Inc   4.04 $ 1,778.600  Millions$ 440.700  Millions
Phibro Animal Health Corporation  3.98 $ 621.801  Millions$ 156.078  Millions
Clearside Biomedical Inc   3.80 $ 40.347  Millions$ 10.607  Millions
Kala Bio inc   3.58 $ 67.846  Millions$ 18.974  Millions
Perrigo Company Plc  3.52 $ 5,667.900  Millions$ 1,611.900  Millions
Apellis Pharmaceuticals Inc   3.48 $ 590.345  Millions$ 169.872  Millions
Ionis Pharmaceuticals Inc  3.42 $ 1,960.989  Millions$ 572.887  Millions
Ascendis Pharma A  3.14 $ 925.557  Millions$ 294.950  Millions

Date modified: 2023-03-23T21:49:59+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com